Abbott Tenders for Bonds Before $16 Billion in Debt Issuance

Abbott Laboratories (ABT) said it will tender for as much as $7.7 billion of bonds as the drug and medical-device company that plans to split in two prepares to raise about $16 billion of debt.

A deal that size would be the biggest since 2009, when a new issue last topped $10 billion, according to data compiled by Bloomberg. The largest offerings this year include a $9.8 billion issue from United Technologies Corp. in May and a $7.5 billion sale from Anheuser-Busch InBev NV in July, Bloomberg data show.

Abbott, which makes the world’s top-selling medicine Humira, made a tender offer for four bonds with $4.75 billion outstanding and as much as 47.2 percent on five other issues with $6.25 billion, the company said today in a statement.

AbbVie Inc., a spinoff of Abbott’s pharmaceutical operations, will raise just under $16 billion of debt in coming weeks, Thomas Freyman, senior vice president, finance and chief financial officer at Abbott said on an Oct. 17 earnings call. AbbVie will make a cash distribution of about $8.5 billion to Abbott which the company will use to help fund the tender and pay down a portion of its commercial paper debt.

Abbott’s corporate credit and senior unsecured ratings were lowered to A+ from AA by Standard & Poor’s today due to the spinoff, the ratings company said in a release.

Third-quarter sales fell 0.4 percent to $9.77 billion from a year earlier, missing the $9.94 billion average of 14 analyst estimates compiled by Bloomberg. Excluding the effect of foreign currency exchange, sales increased 4.1 percent, Abbott said in a statement today.

AbbVie will pay a $1.60 a share annual dividend, while Abbott shareholders will get 56 cents a year.

To contact the reporter on this story: Sarika Gangar in New York at;

To contact the editor responsible for this story Alan Goldstein at;

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.